Eintrag weiter verarbeiten
PB2196 ANTIPLATELET THERAPY IN ESSENTIAL THROMBOCYTHEMIA: LABORATORY STUDY OF LOW‐DOSE ASPIRIN
Gespeichert in:
| Zeitschriftentitel: | HemaSphere |
|---|---|
| Personen und Körperschaften: | , , , |
| In: | HemaSphere, 3, 2019, S1, S. 984-985 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Cacciola, R. Vecchio, V. Cacciola, E. Gentilini Cacciola, E. Cacciola, R. Vecchio, V. Cacciola, E. Gentilini Cacciola, E. |
|---|---|
| author |
Cacciola, R. Vecchio, V. Cacciola, E. Gentilini Cacciola, E. |
| spellingShingle |
Cacciola, R. Vecchio, V. Cacciola, E. Gentilini Cacciola, E. HemaSphere PB2196 ANTIPLATELET THERAPY IN ESSENTIAL THROMBOCYTHEMIA: LABORATORY STUDY OF LOW‐DOSE ASPIRIN Hematology |
| author_sort |
cacciola, r. |
| spelling |
Cacciola, R. Vecchio, V. Cacciola, E. Gentilini Cacciola, E. 2572-9241 2572-9241 Wiley Hematology http://dx.doi.org/10.1097/01.hs9.0000567264.48027.4a <jats:sec><jats:title>Background:</jats:title><jats:p>The essential thrombocythemia (ET) is a myeloid neoplasm characterized by platelet hyperreactivity and thrombosis. The daily low‐dose aspirin (ASA) is a cornerstone in the prevention of the thrombotic events. In the ET an accelerated platelet turnover translates in a renewal of the drug target shortening the duration of cyclooxygenase (COX‐1) inhibition and may dictate new dosing strategies particularly in ASA “low‐responders” patients.</jats:p></jats:sec><jats:sec><jats:title>Aims:</jats:title><jats:p>Therefore, we evaluated platelet count, β‐thromboglobulin (β‐TG) and platelet factor 4 (PF4), as markers of platelet activation, the platelet function activity (PFA), as indicator of ASA platelet sensitivity, the clotting time (CT), clot formation time (CFT) and maximum clot formation/firmness (MCF), as indicators of aspirinated platelet contribution to clot firmness.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We studied 60 patients (20 men, 40 women; mean age 51 years, range 32‐70) with ET according to WHO criteria. The mean duration of disease was 11 years. All patients were on ASA 100 mg once daily. Of the 60 patients, 45 were on anagrelide hydrochloride (daily dose 1.5 mg) (10 men, 35 women), 15 were on hydroxyurea (daily dose 2 mg) (10 men 5 women). None had inherited or acquired thrombotic risk factors. Sixty subjects served as controls. Platelets were measured by automated analyzer. β‐TG and PF4 were determined by ELISA. ASA platelet sensitivity and CT, CFT and MCF were measured by Platelet Function Analyzer (PFA‐100) and by ROTEM delta, respectively.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>The mean platelet count was 455 ± 200 × 109/L. All patients had normal β‐TG and PF4 (12 ± 5 IU/ml and 4 ± 1 IU/ml), prolonged C/EPI closure time (T, unit: s, n.v. 84‐160 s) (249 ± 40 s), normal CT (CT, unit: s. n.v. 100‐240 s) (110 ± 20 s), normal CFT (CFT, unit: s, n.v. 30‐110 s) (45 ± 5 s) and normal MCF (MCF, unit: mm, n.v. 50‐72 mm) (61 ± 2 mm).</jats:p></jats:sec><jats:sec><jats:title>Summary/Conclusion:</jats:title><jats:p>These findings suggest that in ET patients the daily low‐dose ASA represents an optimal dosing strategy.</jats:p></jats:sec> PB2196 ANTIPLATELET THERAPY IN ESSENTIAL THROMBOCYTHEMIA: LABORATORY STUDY OF LOW‐DOSE ASPIRIN HemaSphere |
| doi_str_mv |
10.1097/01.hs9.0000567264.48027.4a |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5Ny8wMS5oczkuMDAwMDU2NzI2NC40ODAyNy40YQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5Ny8wMS5oczkuMDAwMDU2NzI2NC40ODAyNy40YQ |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Wiley, 2019 |
| imprint_str_mv |
Wiley, 2019 |
| issn |
2572-9241 |
| issn_str_mv |
2572-9241 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
cacciola2019pb2196antiplatelettherapyinessentialthrombocythemialaboratorystudyoflowdoseaspirin |
| publishDateSort |
2019 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
HemaSphere |
| source_id |
49 |
| title |
PB2196 ANTIPLATELET THERAPY IN ESSENTIAL THROMBOCYTHEMIA: LABORATORY STUDY OF LOW‐DOSE ASPIRIN |
| title_unstemmed |
PB2196 ANTIPLATELET THERAPY IN ESSENTIAL THROMBOCYTHEMIA: LABORATORY STUDY OF LOW‐DOSE ASPIRIN |
| title_full |
PB2196 ANTIPLATELET THERAPY IN ESSENTIAL THROMBOCYTHEMIA: LABORATORY STUDY OF LOW‐DOSE ASPIRIN |
| title_fullStr |
PB2196 ANTIPLATELET THERAPY IN ESSENTIAL THROMBOCYTHEMIA: LABORATORY STUDY OF LOW‐DOSE ASPIRIN |
| title_full_unstemmed |
PB2196 ANTIPLATELET THERAPY IN ESSENTIAL THROMBOCYTHEMIA: LABORATORY STUDY OF LOW‐DOSE ASPIRIN |
| title_short |
PB2196 ANTIPLATELET THERAPY IN ESSENTIAL THROMBOCYTHEMIA: LABORATORY STUDY OF LOW‐DOSE ASPIRIN |
| title_sort |
pb2196 antiplatelet therapy in essential thrombocythemia: laboratory study of low‐dose aspirin |
| topic |
Hematology |
| url |
http://dx.doi.org/10.1097/01.hs9.0000567264.48027.4a |
| publishDate |
2019 |
| physical |
984-985 |
| description |
<jats:sec><jats:title>Background:</jats:title><jats:p>The essential thrombocythemia (ET) is a myeloid neoplasm characterized by platelet hyperreactivity and thrombosis. The daily low‐dose aspirin (ASA) is a cornerstone in the prevention of the thrombotic events. In the ET an accelerated platelet turnover translates in a renewal of the drug target shortening the duration of cyclooxygenase (COX‐1) inhibition and may dictate new dosing strategies particularly in ASA “low‐responders” patients.</jats:p></jats:sec><jats:sec><jats:title>Aims:</jats:title><jats:p>Therefore, we evaluated platelet count, β‐thromboglobulin (β‐TG) and platelet factor 4 (PF4), as markers of platelet activation, the platelet function activity (PFA), as indicator of ASA platelet sensitivity, the clotting time (CT), clot formation time (CFT) and maximum clot formation/firmness (MCF), as indicators of aspirinated platelet contribution to clot firmness.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We studied 60 patients (20 men, 40 women; mean age 51 years, range 32‐70) with ET according to WHO criteria. The mean duration of disease was 11 years. All patients were on ASA 100 mg once daily. Of the 60 patients, 45 were on anagrelide hydrochloride (daily dose 1.5 mg) (10 men, 35 women), 15 were on hydroxyurea (daily dose 2 mg) (10 men 5 women). None had inherited or acquired thrombotic risk factors. Sixty subjects served as controls. Platelets were measured by automated analyzer. β‐TG and PF4 were determined by ELISA. ASA platelet sensitivity and CT, CFT and MCF were measured by Platelet Function Analyzer (PFA‐100) and by ROTEM delta, respectively.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>The mean platelet count was 455 ± 200 × 109/L. All patients had normal β‐TG and PF4 (12 ± 5 IU/ml and 4 ± 1 IU/ml), prolonged C/EPI closure time (T, unit: s, n.v. 84‐160 s) (249 ± 40 s), normal CT (CT, unit: s. n.v. 100‐240 s) (110 ± 20 s), normal CFT (CFT, unit: s, n.v. 30‐110 s) (45 ± 5 s) and normal MCF (MCF, unit: mm, n.v. 50‐72 mm) (61 ± 2 mm).</jats:p></jats:sec><jats:sec><jats:title>Summary/Conclusion:</jats:title><jats:p>These findings suggest that in ET patients the daily low‐dose ASA represents an optimal dosing strategy.</jats:p></jats:sec> |
| container_issue |
S1 |
| container_start_page |
984 |
| container_title |
HemaSphere |
| container_volume |
3 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792343774430494731 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:57:02.549Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=PB2196+ANTIPLATELET+THERAPY+IN+ESSENTIAL+THROMBOCYTHEMIA%3A+LABORATORY+STUDY+OF+LOW%E2%80%90DOSE+ASPIRIN&rft.date=2019-06-01&genre=article&issn=2572-9241&volume=3&issue=S1&spage=984&epage=985&pages=984-985&jtitle=HemaSphere&atitle=PB2196+ANTIPLATELET+THERAPY+IN+ESSENTIAL+THROMBOCYTHEMIA%3A+LABORATORY+STUDY+OF+LOW%E2%80%90DOSE+ASPIRIN&aulast=Cacciola&aufirst=E.&rft_id=info%3Adoi%2F10.1097%2F01.hs9.0000567264.48027.4a&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792343774430494731 |
| author | Cacciola, R., Vecchio, V., Cacciola, E. Gentilini, Cacciola, E. |
| author_facet | Cacciola, R., Vecchio, V., Cacciola, E. Gentilini, Cacciola, E., Cacciola, R., Vecchio, V., Cacciola, E. Gentilini, Cacciola, E. |
| author_sort | cacciola, r. |
| container_issue | S1 |
| container_start_page | 984 |
| container_title | HemaSphere |
| container_volume | 3 |
| description | <jats:sec><jats:title>Background:</jats:title><jats:p>The essential thrombocythemia (ET) is a myeloid neoplasm characterized by platelet hyperreactivity and thrombosis. The daily low‐dose aspirin (ASA) is a cornerstone in the prevention of the thrombotic events. In the ET an accelerated platelet turnover translates in a renewal of the drug target shortening the duration of cyclooxygenase (COX‐1) inhibition and may dictate new dosing strategies particularly in ASA “low‐responders” patients.</jats:p></jats:sec><jats:sec><jats:title>Aims:</jats:title><jats:p>Therefore, we evaluated platelet count, β‐thromboglobulin (β‐TG) and platelet factor 4 (PF4), as markers of platelet activation, the platelet function activity (PFA), as indicator of ASA platelet sensitivity, the clotting time (CT), clot formation time (CFT) and maximum clot formation/firmness (MCF), as indicators of aspirinated platelet contribution to clot firmness.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We studied 60 patients (20 men, 40 women; mean age 51 years, range 32‐70) with ET according to WHO criteria. The mean duration of disease was 11 years. All patients were on ASA 100 mg once daily. Of the 60 patients, 45 were on anagrelide hydrochloride (daily dose 1.5 mg) (10 men, 35 women), 15 were on hydroxyurea (daily dose 2 mg) (10 men 5 women). None had inherited or acquired thrombotic risk factors. Sixty subjects served as controls. Platelets were measured by automated analyzer. β‐TG and PF4 were determined by ELISA. ASA platelet sensitivity and CT, CFT and MCF were measured by Platelet Function Analyzer (PFA‐100) and by ROTEM delta, respectively.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>The mean platelet count was 455 ± 200 × 109/L. All patients had normal β‐TG and PF4 (12 ± 5 IU/ml and 4 ± 1 IU/ml), prolonged C/EPI closure time (T, unit: s, n.v. 84‐160 s) (249 ± 40 s), normal CT (CT, unit: s. n.v. 100‐240 s) (110 ± 20 s), normal CFT (CFT, unit: s, n.v. 30‐110 s) (45 ± 5 s) and normal MCF (MCF, unit: mm, n.v. 50‐72 mm) (61 ± 2 mm).</jats:p></jats:sec><jats:sec><jats:title>Summary/Conclusion:</jats:title><jats:p>These findings suggest that in ET patients the daily low‐dose ASA represents an optimal dosing strategy.</jats:p></jats:sec> |
| doi_str_mv | 10.1097/01.hs9.0000567264.48027.4a |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5Ny8wMS5oczkuMDAwMDU2NzI2NC40ODAyNy40YQ |
| imprint | Wiley, 2019 |
| imprint_str_mv | Wiley, 2019 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 2572-9241 |
| issn_str_mv | 2572-9241 |
| language | English |
| last_indexed | 2024-03-01T16:57:02.549Z |
| match_str | cacciola2019pb2196antiplatelettherapyinessentialthrombocythemialaboratorystudyoflowdoseaspirin |
| mega_collection | Wiley (CrossRef) |
| physical | 984-985 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | HemaSphere |
| source_id | 49 |
| spelling | Cacciola, R. Vecchio, V. Cacciola, E. Gentilini Cacciola, E. 2572-9241 2572-9241 Wiley Hematology http://dx.doi.org/10.1097/01.hs9.0000567264.48027.4a <jats:sec><jats:title>Background:</jats:title><jats:p>The essential thrombocythemia (ET) is a myeloid neoplasm characterized by platelet hyperreactivity and thrombosis. The daily low‐dose aspirin (ASA) is a cornerstone in the prevention of the thrombotic events. In the ET an accelerated platelet turnover translates in a renewal of the drug target shortening the duration of cyclooxygenase (COX‐1) inhibition and may dictate new dosing strategies particularly in ASA “low‐responders” patients.</jats:p></jats:sec><jats:sec><jats:title>Aims:</jats:title><jats:p>Therefore, we evaluated platelet count, β‐thromboglobulin (β‐TG) and platelet factor 4 (PF4), as markers of platelet activation, the platelet function activity (PFA), as indicator of ASA platelet sensitivity, the clotting time (CT), clot formation time (CFT) and maximum clot formation/firmness (MCF), as indicators of aspirinated platelet contribution to clot firmness.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We studied 60 patients (20 men, 40 women; mean age 51 years, range 32‐70) with ET according to WHO criteria. The mean duration of disease was 11 years. All patients were on ASA 100 mg once daily. Of the 60 patients, 45 were on anagrelide hydrochloride (daily dose 1.5 mg) (10 men, 35 women), 15 were on hydroxyurea (daily dose 2 mg) (10 men 5 women). None had inherited or acquired thrombotic risk factors. Sixty subjects served as controls. Platelets were measured by automated analyzer. β‐TG and PF4 were determined by ELISA. ASA platelet sensitivity and CT, CFT and MCF were measured by Platelet Function Analyzer (PFA‐100) and by ROTEM delta, respectively.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>The mean platelet count was 455 ± 200 × 109/L. All patients had normal β‐TG and PF4 (12 ± 5 IU/ml and 4 ± 1 IU/ml), prolonged C/EPI closure time (T, unit: s, n.v. 84‐160 s) (249 ± 40 s), normal CT (CT, unit: s. n.v. 100‐240 s) (110 ± 20 s), normal CFT (CFT, unit: s, n.v. 30‐110 s) (45 ± 5 s) and normal MCF (MCF, unit: mm, n.v. 50‐72 mm) (61 ± 2 mm).</jats:p></jats:sec><jats:sec><jats:title>Summary/Conclusion:</jats:title><jats:p>These findings suggest that in ET patients the daily low‐dose ASA represents an optimal dosing strategy.</jats:p></jats:sec> PB2196 ANTIPLATELET THERAPY IN ESSENTIAL THROMBOCYTHEMIA: LABORATORY STUDY OF LOW‐DOSE ASPIRIN HemaSphere |
| spellingShingle | Cacciola, R., Vecchio, V., Cacciola, E. Gentilini, Cacciola, E., HemaSphere, PB2196 ANTIPLATELET THERAPY IN ESSENTIAL THROMBOCYTHEMIA: LABORATORY STUDY OF LOW‐DOSE ASPIRIN, Hematology |
| title | PB2196 ANTIPLATELET THERAPY IN ESSENTIAL THROMBOCYTHEMIA: LABORATORY STUDY OF LOW‐DOSE ASPIRIN |
| title_full | PB2196 ANTIPLATELET THERAPY IN ESSENTIAL THROMBOCYTHEMIA: LABORATORY STUDY OF LOW‐DOSE ASPIRIN |
| title_fullStr | PB2196 ANTIPLATELET THERAPY IN ESSENTIAL THROMBOCYTHEMIA: LABORATORY STUDY OF LOW‐DOSE ASPIRIN |
| title_full_unstemmed | PB2196 ANTIPLATELET THERAPY IN ESSENTIAL THROMBOCYTHEMIA: LABORATORY STUDY OF LOW‐DOSE ASPIRIN |
| title_short | PB2196 ANTIPLATELET THERAPY IN ESSENTIAL THROMBOCYTHEMIA: LABORATORY STUDY OF LOW‐DOSE ASPIRIN |
| title_sort | pb2196 antiplatelet therapy in essential thrombocythemia: laboratory study of low‐dose aspirin |
| title_unstemmed | PB2196 ANTIPLATELET THERAPY IN ESSENTIAL THROMBOCYTHEMIA: LABORATORY STUDY OF LOW‐DOSE ASPIRIN |
| topic | Hematology |
| url | http://dx.doi.org/10.1097/01.hs9.0000567264.48027.4a |